Evercore ISI Group Maintains Outperform on Vir Biotechnology, Raises Price Target to $25
Benzinga Newsdesk 2 hours ago
Analyst RatingsNewsPrice Target
Evercore ISI Group analyst Cory Kasimov maintains Vir Biotechnology (NASDAQ:VIR) with a Outperform and raises the price target from $22 to $25.
Evercore ISI Group analyst Cory Kasimov maintains Vir Biotechnology (NASDAQ:VIR) with a Outperform and raises the price target from $22 to $25.